Marie Thibault
Stock Analyst at BTIG
(3.21)
# 1,032
Out of 5,180 analysts
118
Total ratings
42.48%
Success rate
2.7%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KMTS Kestra Medical Technologies | Reiterates: Buy | $32 | $18.33 | +74.58% | 3 | Mar 25, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $61.90 | +37.32% | 11 | Mar 9, 2026 | |
| DCTH Delcath Systems | Maintains: Buy | $23 → $19 | $8.89 | +113.72% | 5 | Feb 26, 2026 | |
| PODD Insulet | Reiterates: Buy | $380 | $208.01 | +82.68% | 7 | Feb 18, 2026 | |
| MASI Masimo | Downgrades: Neutral | n/a | $177.32 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $28.26 | +91.08% | 8 | Feb 18, 2026 | |
| OM Outset Medical | Maintains: Buy | $17 → $15 | $3.61 | +315.51% | 3 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Buy | $103 | $79.50 | +29.56% | 3 | Feb 11, 2026 | |
| BSX Boston Scientific | Reiterates: Buy | $110 | $62.93 | +74.80% | 16 | Feb 9, 2026 | |
| EMBC Embecta | Reiterates: Buy | $25 | $8.84 | +182.81% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $88 | $54.93 | +60.20% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2 | $0.34 | +487.89% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $17.76 | +68.92% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $101.88 | +37.42% | 15 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $114.21 | +88.25% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.07 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $54.69 | +18.85% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.67 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.27 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.18 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $311.23 | -98.07% | 1 | Apr 9, 2020 |
Kestra Medical Technologies
Mar 25, 2026
Reiterates: Buy
Price Target: $32
Current: $18.33
Upside: +74.58%
DexCom
Mar 9, 2026
Reiterates: Buy
Price Target: $85
Current: $61.90
Upside: +37.32%
Delcath Systems
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $8.89
Upside: +113.72%
Insulet
Feb 18, 2026
Reiterates: Buy
Price Target: $380
Current: $208.01
Upside: +82.68%
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $177.32
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $28.26
Upside: +91.08%
Outset Medical
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $3.61
Upside: +315.51%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Buy
Price Target: $103
Current: $79.50
Upside: +29.56%
Boston Scientific
Feb 9, 2026
Reiterates: Buy
Price Target: $110
Current: $62.93
Upside: +74.80%
Embecta
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $8.84
Upside: +182.81%
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $54.93
Upside: +60.20%
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.34
Upside: +487.89%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $17.76
Upside: +68.92%
Jan 23, 2026
Maintains: Buy
Price Target: $145 → $140
Current: $101.88
Upside: +37.42%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $114.21
Upside: +88.25%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.07
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $54.69
Upside: +18.85%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.67
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $6.18
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $311.23
Upside: -98.07%